Clinical Trial Update: Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 safety study of Enapotamab Vedotin in solid tumors, including ovarian and cervical cancer; completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Endometrial Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Sarcoma
• Solid Tumors
• Thyroid Cancer

Drugs mentioned

• Enapotamab Vedotin (enapotamab vedotin)

Snippet

Sponsor: Genmab | Conditions: Ovarian Cancer, Cervical Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-01-05